Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

Tumor staging was reconfirmed according to the 8th Edition of the American Joint Committee on Cancer (AJCC) TNM Classification for Lung Cancer (18 ... patients were adenocarcinoma (n=61), squamous ...

The test processes whole-slide images of non-small cell lung cancer tissue to provide a quantitative TROP2 score, which Roche says provides a level of precision beyond manual methods. TROP2 has ...

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access. In this clip, Raymond Osarogiagbon, MD ...

The VENTANA TROP2 (EPR20043) RxDx Device analyses whole slide images of non-small cell lung cancer (NSCLC) tissue stained with TROP2 to compute a quantitative TROP2 score. The algorithm incorporates ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in previously treated patients with advanced non-small cell lung cancer ...

In idiopathic pulmonary fibrosis (IPF), higher risk of mortality and lung transplant is associated with small decreases in percent predicted values for forced vital capacity (FVC) and diffusing ...